Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam, Inc. (NASDAQ: BEAT) has acquired substantially all assets of LIVMOR, a digital health solutions company, enhancing its capabilities in remote cardiac monitoring. This acquisition includes the FDA-cleared Halo+™ Atrial Fibrillation Detection System, the first prescription wearable for continuous monitoring of cardiac rhythms. Founded in 2016, LIVMOR's technology has been deployed in the VA Healthcare System in Dallas, Texas. The strategic move is expected to integrate LIVMOR's cloud-based software with HeartBeam's existing solutions, potentially improving patient outcomes and reducing healthcare costs. Financial terms remain undisclosed.
HeartBeam, Inc. (NASDAQ: BEAT) announced a senior leadership change with Robert Eno stepping in as Executive Vice President and Chief Business Officer, taking over from Jon Hunt, who will now serve as a strategic advisor and consultant. This transition is effective March 15, 2023. The company is preparing for key milestones in 2023, including FDA clearance for the HeartBeam AIMI™ system and submission for the AIMIGo™ product. Dr. Hunt has played a crucial role in product development and market introduction efforts, while Eno is expected to bring fresh perspectives for commercialization strategies.
HeartBeam, Inc. (NASDAQ: BEAT), a company specializing in cardiac technology, will hold a conference call on Thursday, March 16, 2023, at 4:30 p.m. Eastern time to discuss its fourth quarter and full fiscal year results for 2022. The call will cover recent announcements, ongoing initiatives, and key milestones for 2023. Attendees can access the call via a webcast or by dial-in options. A replay will be available until June 16, 2023. HeartBeam has developed a unique 3D-vector ECG platform for heart attack detection.
HeartBeam, Inc. (NASDAQ: BEAT) has appointed Robert Eno as President, a newly created role aimed at enhancing the company's strategic and operational capabilities. Eno brings over 28 years of experience in developing markets for innovative medical technologies. He will be instrumental in the strategic direction and commercialization of HeartBeam's AIMI™ and AIMIGo™ platforms, which are designed for remote heart attack detection. HeartBeam, known for its unique 3D-vector ECG platform, seeks to establish itself as a leader in ambulatory cardiology.
HeartBeam, Inc. (NASDAQ: BEAT) announced the issuance of a patent for its AIMIGo™ device, which provides 12-lead ECG capability, enhancing heart attack detection. This patent, granted by the European Patent Office, covers several European countries, validating HeartBeam's innovative technology. With over 11 million new cardiovascular disease cases annually in Europe, the AIMIGo device aims to allow patients to monitor their heart health outside medical settings. The innovation supports timely diagnosis and intervention for cardiac patients.
HeartBeam, Inc. (NASDAQ: BEAT) has announced significant advancements in their cardiac technology products, particularly the HeartBeam AIMIGo and HeartBeam AIMI systems, aimed at enhancing heart attack detection. The company anticipates regulatory approval for the HeartBeam AIMI system in Q1 2023 and plans to submit HeartBeam AIMIGo for FDA clearance soon. HeartBeam aims to transform patient care by providing remote heart attack detection with their innovative 12-lead 3D vector ECG technology. They have also strengthened their intellectual property with several new patents, positioning themselves for growth in the healthcare market.
HeartBeam, Inc. (NASDAQ: BEAT) has partnered with Evolve Manufacturing Technologies to manufacture the AIMIGo 3D vector electrocardiogram (VECG) device. This credit card-sized device facilitates remote heart attack detection and is expected to enter early market testing in Q2 2023, pending FDA clearance. The AIMIGo solution aims to enhance heart attack detection for patients outside medical settings, addressing a significant need as more than 18 million U.S. citizens suffer from coronary artery disease.
HeartBeam, Inc. (NASDAQ: BEAT) has received an allowed patent for a 12-lead ECG smartwatch designed to detect heart attacks and complex cardiac arrhythmias, according to a recent announcement. This innovative technology aims to disrupt the multi-billion dollar wearable device market, which is projected to reach $196B by 2030. HeartBeam's platform enables diagnostic capabilities outside traditional medical settings, positioning the company favorably in a rapidly expanding market.
HeartBeam, Inc. (NASDAQ: BEAT) announced the submission of its HeartBeam AIMI™ platform for FDA clearance, enhancing its heart attack detection technology. The company also plans to submit the AIMIGo telehealth solution by Q4 2022. With two new patents granted, HeartBeam aims to expand its product pipeline to include smartwatch connectivity. Financially, the company reported a net loss of $3.6 million for Q3 2022, up from $1.2 million the previous year, with research and development expenses reaching $1.6 million. Cash reserves stood at $6.5 million as of September 30, 2022.
HeartBeam, Inc. (NASDAQ: BEAT), a leader in cardiac technology, will hold a conference call on November 10, 2022, at 4:30 p.m. Eastern time to discuss its Q3 results for the period ending September 30, 2022. CEO Branislav Vajdic, PhD, CFO Richard Brounstein, and CBO Jon Hunt, PhD, will lead the call, reviewing recent announcements and future milestones. A press release detailing results will precede the call. Investors can access the call via dial-in or webcast, and a replay will be available until February 10, 2023.